Business Wire

IL-NEXTSENSE

Share
NextSense Emerges to Unlock Brain Health with Key Partners UCB, Heraeus, UC San Diego, and Emory University

NextSense, the foundation of brain health, came out of stealth with an announcement made from the AES (American Epilepsy Society) Annual Meeting in Chicago, where NextSense and its partners are presenting the results of their research on seizure detection to peers in academia and industry for the first time.

NextSense unlocks brain health with real world data insights and practical, scientific wisdom for daily living. Traditional brain health monitoring technology like EEG machines and polysomnograms are too bulky for home use, requiring patients to stay overnight at hospitals or sleep study clinics for observation. The high cost of care and lack of comfort of these devices makes long-term and continuous monitoring nearly impossible. Not only are these data based on a single timeframe, they observe what is anything but an ordinary night’s sleep. And for anyone living with epilepsy, the unpredictability of seizures makes direct observation and high-quality data-gathering exceedingly rare.

The NextSense platform starts with longitudinal EEG data collected at the point of experience with biosensing earbuds that can be worn comfortably at night and as-needed throughout the day. The company envisions combining that data with environmental and behavioral patterns collected from smart devices and timely analysis from its team of neuroscientists to help doctors identify triggers, diagnose certain conditions and tailor treatment and medication recommendations in real-time.

At the AES Annual Meeting, NextSense detailed for the first time its key relationship with biopharma partner UCB. The company also revealed research and IP agreements with both Heraeus and UC San Diego, as well as a multi-dimensional collaboration with researchers at Emory University.

“We believe that technologies that enable earlier detection of seizures and improve the coordination of care for people living with epilepsy complement UCB’s strong heritage in epilepsy and portfolio of medicines,” said Colin Lake, Vice President of Digital Business Transformation for Neurology at UCB. “Being able to access meaningful data that NextSense can provide will allow us to capture insights and solve complex disease questions that will help epilepsy patients on their care journey achieve better outcomes.”

Each pharma and biotech company has partnered with NextSense to study how neurologists can better calibrate and manage treatment plans for epilepsy, sleep, and potentially other CNS disorders, using the company’s platform.

Emory University’s Brain Health Center, led by world-renowned physician-scientist Allan Levey, is the site of multiple NextSense studies and its first two clinical trials.

"We're excited for what this partnership means for both NextSense and Emory Brain Health," said Allan Levey, Founding Director of Goizueta Institute at Emory Brain Health. "Our work alongside Emory's Department of Biomedical Informatics signifies a notable step forward toward chronic ambulatory monitoring of brain physiology via EEG. With their earbuds allowing access for monitoring data over much longer periods of time, the initial findings and foundational work are very promising and showing how their efforts and technology has significant potential to revolutionize the approach to diagnosing and treating many neurological disorders in the future."

“We’ve assembled a dream team of collaborators,” said Jonathan Berent, Founder and CEO of NextSense. “It is a personal and professional thrill to partner with these innovators at the very top of their field. Our partners have worked with us shoulder-to-shoulder to methodically pursue what many people said was impossible. We are beyond excited to begin to show the world what we have achieved, starting with the scientific community at AES.”

NextSense is continuing to enroll participants in clinical trials focused on epilepsy and sleep. Eventually, the company hopes to leverage the long-term data collected to help establish biomarkers for brain health.

“Whether someone is living with epilepsy, struggling to stay alert, or seeking an elusive diagnosis for a neurological condition, we’re offering hope,“ said Jen Dwyer, Medical Director of NextSense. “We see our members from every angle, and we understand their unique pain points. We’re working towards a world where those who suffer from these conditions don’t have to choose between comfort and accuracy. And we’re just getting started.”

About NextSense, Inc.

NextSense is the foundation of a healthy brain.

We unlock brain health with real-world data insights and practical, scientific wisdom for daily living. Whether you are struggling to stay alert, living with something like epilepsy, seeking an elusive diagnosis for a neurological condition, we can help.

We are a passionate team of neuroscientists and venture operators on a mission to catalyze brain health in both science and culture.

To learn more, please visit: www.nextsense.io

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

YES Announces Leadership Transition as Rezwan Lateef Appointed Chief Executive Officer3.12.2025 20:24:00 CET | Press release

YES (Yield Engineering Systems), a leading provider of high-performance process solutions for the semiconductor Advanced Packaging market, today announced that Rezwan Lateef has been appointed Chief Executive Officer. Mr. Lateef previously served as President of YES and has been a key driver of the company’s significant growth, global expansion, and product innovation over the past several years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202200541/en/ Rezwan Lateef, CEO of YES. The transition marks a natural progression for the company as it surpasses a key revenue milestone and enters its next phase of scaling with top tier semiconductor and AI computing customers. Rama Alapati, who has served as CEO since 2021, will step into a consulting role to support Mr. Lateef during the transition period and ensure strong organizational continuity. “Rama has played an instrumental role in elevating YES from a promising techno

Doha Debates Examines How Entertainment Shapes Us Today3.12.2025 18:13:00 CET | Press release

In a new episode, leading thinkers and students debate whether today’s entertainment elevates us or pulls us into distraction. Qatar Foundation’s Doha Debates continues its flagship debate series with a new episode that examines how modern entertainment shapes our attention, creativity, and everyday well-being. Moderated by Dareen Abughaida, the debate brings together three influential thinkers to ask whether today’s entertainment landscape is enriching us—or overwhelming us. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251203737439/en/ Doha Debates examines how entertainment shapes us today in a new episode, leading thinkers and students debate whether today’s entertainment elevates us or pulls us into distraction. (Photo: AETOSWire) This week’s debate features Marya Bangee, Senior Advisor at the Pop Culture Collaborative; Dr. Anna Lembke, Professor of Psychiatry at Stanford University and author of Dopamine Nation; and N

Vycellix Prepares for First-in-Human Study of Novel Allogeneic Cell Therapy Powered by Its Universal Cell Engineering Platform3.12.2025 18:00:00 CET | Press release

- Single-step CD45-engager technology shows robust immune evasion with functional persistence in pre-clinical models - Phase 1 study to evaluate ‘off-the-shelf’ natural killer cell cancer immunotherapy in the treatment of multiple myeloma Vycellix, Inc., a biotechnology company developing next-generation allogeneic cell therapies designed to overcome the risk of immune rejection, today announced the successful completion of pre-clinical development for its universal cell engineering platform (VY-UC) with rigorous studies across many donor cell types proving robust immune evasion with functional persistence. The Company is now preparing for first-in-human clinical validation by seeking regulatory approval in Sweden to initiate a Phase 1 study for its lead VY-UC product candidate, a novel, off-the-shelf natural killer (NK) cell therapy (VNK-101) for patients with relapsed or refractory multiple myeloma. VY-UC is a single-step CD45 engager strategy intended to address a central barrier to

Andersen Consulting forstærker platformen med Peers Technology + Consulting3.12.2025 17:45:00 CET | Pressemeddelelse

Andersen Consulting tilføjer samarbejdspartneren Peers Consulting + Technology, et brasiliansk firma kendt for at fremme strategiske forandringer gennem digital innovation og avanceret analyse. Peers blev stiftet i 2012 og leverer helhedsorienterede løsninger, der kombinerer strategisk indsigt med digital eksekvering. Deres ydelser spænder over avanceret analyse og generativ ai, it-strategi, kundeoplevelse, finans, cybersikkerhed, bæredygtighed, forsyningskæde, M&A og organisatorisk transformation. Peers er anerkendt for sin indflydelse i hele Latinamerika og ruster kunder til at modernisere driften, forbedre beslutningstagningen og skabe bæredygtige resultater. “Vi tror på, at meningsfuld transformation sker i krydsfeltet mellem data, teknologi og menneskelig indsigt,” udtaler administrerende partner Pedro Ribeiro. “Vi arbejder side om side med vores kunder for at omdanne udfordringer til vækst. Samarbejdet med Andersen Consulting giver os mulighed for at udbrede denne tilgang globalt

DevvStream and Southern Energy Renewables Announce Business Combination Targeting Low-Cost Production of Carbon-Negative SAF and Green Methanol3.12.2025 15:40:00 CET | Press release

Combination integrates carbon-credit origination expertise with U.S.-produced, lower-cost carbon-negative fuels to meet growing global demandSouthern secures a $402 million bond allocation from the Louisiana Community Development Authority in support of its flagship biomass-to-fuel facilitySouthern makes initial PIPE Investment in DevvStream of approximately $2.0 million at $15.58 per share DevvStream Corp. (Nasdaq: DEVS) (“DevvStream”), a leading carbon management and environmental-asset monetization firm, and Southern Energy Renewables Inc. (“Southern”), a U.S.-based producer of low-cost fuels made from biomass, with a flagship Louisiana project that plans to utilize regional wood-waste biomass to deliver green methanol and carbon-negative sustainable aviation fuel (“SAF”) at scale, today announced that they have entered into a definitive agreement to combine under a new U.S.-domiciled, Nasdaq-listed company, following customary closing conditions. The new company plans to help aviat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye